Growing the gout market has been slow going for Ironwood, which last year forayed into the space by grabbing AstraZeneca’s Zurampic. But now, the company has a new catalyst. More: Ironwood's gout franchise gets a lift with Duzallo combo approval
read moreGeneric drug prices may be depressed enough to bring down the mood of many a copycat drugmaker, but that doesn’t mean prices on some unusual formulas aren’t going up. Just ask Hikma, which posted a half-dozen price rises that topped
read morePfizer’s new targeted drug for the treatment of acute lymphoblastic leukemia (ALL) last week won FDA approval after already getting a nod by the EU. But U.K. cost watchdog NICE today snubbed Besponsa, eliciting a quick and heated response from
read moreCancer patient David Mitchell is so concerned about the potentially high price of CAR-T treatments that he requested a meeting with Joe Jimenez, CEO of Novartis, as the company works to establish a price for its upcoming product in this
read moreWith a win in a federal court in Mississippi, Bayer and Johnson & Johnson are now three for three in fending off lawsuits over the bleeding risks of blockbuster blood thinner Xarelto. More: Bayer, Johnson & Johnson notch win number
read moreThe company and Medicines for Malaria Venture launch trial for next-gen antimalarial compound More: Novartis takes aim at drug-resistant Malaria Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals